

# Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Revolution Medicines, Inc.
Enrollment	900 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed pancreatic adenocarcinoma.
- Diagnosis of metastatic disease d 6 weeks prior to informed consent.
- Documented RAS mutation status, either mutant or wild-type.

... and 3 more (see full listing online)

### Exclusion (5)

- Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting.
- Active or known history of untreated central nervous system metastatic disease.
- Any conditions that may affect the ability to take or absorb study drug.
- Major surgery within 28 days prior to randomization.
- Patient is unable or unwilling to comply with protocol-required study visits or procedures.

## Locations (2 total)

---

Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States  
Taylor Cancer Research Center, Maumee, Ohio, United States